Alnylam Pharmaceuticals, Inc.

ALNY · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$251-$66-$57-$84
Dep. & Amort.$14$14$14-$21
Deferred Tax$6$10$10$0
Stock-Based Comp.$108$112$57$92
Change in WC-$205$50-$217-$74
Other Non-Cash$151$35$75-$8
Operating Cash Flow$325$154-$118-$95
Investing Activities
PP&E Inv.-$12-$14-$9-$9
Net Acquisitions$0$0$0$0
Inv. Purchases-$210-$469-$450-$487
Inv. Sales/Matur.$723$332$524$443
Other Inv. Act.-$0$9$49-$0
Investing Cash Flow$501-$141$114-$53
Financing Activities
Debt Repay.-$494$0$0$0
Stock Issued-$131$81$49$36
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$176-$27-$5-$5
Financing Cash Flow-$448$54$44$31
Forex Effect-$1$28$14-$17
Net Chg. in Cash$377$94$54-$134
Supplemental Information
Beg. Cash$1,116$1,022$969$1,102
End Cash$1,493$1,116$1,022$969
Free Cash Flow$313$139-$127-$104